jc
jc

News Center

Check category
/
/
/
Concerned Zhang: J-Valve valve technology to the world

Concerned Zhang: J-Valve valve technology to the world

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-02-03 14:50
  • Views:

(Summary description)

Concerned Zhang: J-Valve valve technology to the world

(Summary description)

  • Categories:News Channel
  • Author:
  • Origin:
  • Time of issue:2017-02-03 14:50
  • Views:
Information

  The original title: concern 丨 Zhang: J-Valve valve technology to the world


  Concerned Zhang: J-Valve valve technology to the world
  The G20 Leaders' 11th summit will be held in Hangzhou, Zhejiang Province in September this year. G20 technical cooperation between countries and exchanges to become the highlight of the international expectations of the meeting. It is understood that the medical field of J-Valve heart valve technology, is expected to become the Chinese science and technology industry and G20 national technical exchange representative project.
  August 1, in the WeChat circle of friends, Suzhou Jie Cheng Medical Technology Co., Ltd. Deputy General Manager Wei Wei timely share a message: Jincheng medical official website officially launched!
  A month ago in Beijing, the State Food and Drug Administration organized by the innovative medical device special approval demonstration, 13 industry experts recently "critical" to assess the J-Valve valve replacement technology products, which is listed before the "last one kilometer".
  "I have done nearly 30 years of cardiac surgery clinician, with 10 years to successfully patented technology landing, and now spent 6 years in the country successfully completed the promotion and clinical trials." Suzhou Jie Cheng Medical Technology Co., Ltd. Director Long, general manager, J-Valve heart valve technology inventor Dr. Zhang said, "Now the technology has been perfect and mature, the relevant state regulatory approval, can be widely used in clinical, domestic and even the world heart valve patients really benefit."


  Wall outside the flower wall outside the incense
  In February 2016, Canada's largest heart surgery center, Vancouver, St. Paul's Hospital, for a case of severe aortic insufficiency in patients with successful minimally invasive heart valve replacement. For his surgery is the Canadian health care workers, surgical use of medical equipment "special grant" from China - Zhang's entrepreneurial research and development team.
  In the past need a few hours or even ten hours of thoracotomy, this time not open chest, heart non-stop, in a very short period of time successfully ended, the patient regained a new life. After the completion of the operation, the patient 6 hours to sit and eat, 3 days out of hospital. Up to the current hospital follow-up shows that patients with good physical recovery.
  The success of the operation of the news, the world of heart surgery in the field of vibration, the Chinese Consul General Vancouver Liu Fei and Zhang pole met, "This is China's first intellectual property rights of medical technology for the first time into the developed countries." Chinese Consul in Vancouver Liu Fei in accept Media interview publicly pointed out.
  In 2009, Zhang was established in Suzhou Jie Cheng Medical Technology Co., Ltd., settled in Suzhou Wujiang Economic and Technological Development Zone Science and Technology Park.
  Entrepreneurship soon, "artificial heart valve technology" to obtain the China Medical Device Industry Association, Wu Jieping Medical Foundation and other units awarded the "China Medical Device Technology Innovation Award." August 2010 product inventor Zhang pole doctor was named "Wujiang City science and technology leading talent"; June 2011, Dr. Zhang selected "Gu Su innovation and entrepreneurship talent"; in October 2013, Dr. Zhang selected tenth Batch "National Thousand Talents Program" in June 2014 the company was "Suzhou City Science and Technology SMEs"; January 2015 Zhang won the "top ten charm of Suzhou City Science and Technology figures."
  Compared with the traditional medical technology, J-Valve valve replacement technology products, is "precision positioning device heart valve implant system." This is a minimally invasive surgical technique and product. Compared with the traditional method of treatment of heart valve disease, it has no need to thoracotomy, no blood circulation, can significantly reduce the patient's surgical trauma, shorten the recovery time, reduce the pain of patients, reduce the physical condition of the patient requirements, thus Expand the scope of application, improve the treatment effect, reduce the cost of surgery, so that most need to replace the heart valve patients can be treated.
  Since the beginning of 2014, J-Valve valve replacement system has successively carried out clinical trials in three large well-known hospitals in China: West China Hospital of Sichuan University, Zhongshan Hospital of Fudan University in Shanghai and Fuwai Cardiovascular Hospital of Chinese Academy of Medical Sciences. Up to now has successfully completed more than 100 cases of clinical trials.
  The clinical case of the above-mentioned Chinese in the "American Journal of Cardiology" (JACC) published, the sensation of the global heart medical field. JACC is the world's leading journal of heart disease research, the world's only large, with significant clinical significance of the study can be published. This is also the Canadian "special grant" to carry out the first application from the Chinese medical products, an important reason for surgery.


  From the expert's approval
  "I have not seen a domestic high-end medical equipment, such as J-Valve can be done with the original." Shanghai Fudan University, Zhongshan Hospital, deputy director of the Department of Cardiology Wei Lai highly recognized, "This can be said that the world's most advanced Of the valve disease treatment technology, Zhang Kui developed technology products to solve the world - class problems.
  In layman's terms, the valve is the door of the heart. Only the door smoothly open and close, smooth, the heart can be healthy and effective blood supply, once the valve stenosis or closed insufficiency, the heart will be lack of power, causing heart failure.
  Authoritative data show that heart failure has become the first cause of death in humans, and heart valve stenosis and insufficiency is one of the most important causes of heart failure. China is a high incidence of heart valve disease, with more than 2 million patients, the need for surgical patients each year more than 200,000, but in China can really accept the surgical treatment of patients is less than 1 /
  "This is because the traditional heart surgery is difficult, high risk." Sichuan University West China Hospital, deputy director of Cardiovascular Surgery Guo Yingjiang that "traditional heart valve surgery there are two ways, one is thoracotomy, one is the cardiopulmonary bypass.
  Guo Yingqiang introduction, thoracotomy surgery in the neck below the patient, the chest out of 30 cm long incision, while the doctor's hand with the manual replacement valve, the general operation time up to 3 to 4 hours, the patient needs to endure great pain and blood loss, After surgery also experienced a long recovery period.
  "Cardiopulmonary bypass is the body's blood into the extracorporeal circulation machine, instead of heart function. Cardiopulmonary bypass can not completely simulate the heart function, will bring harm to the patient, especially to the patient's other organs have a great impact, such as the brain, liver , Kidney and lung, "Guo Yingqiang continued to explain," for seventy-eight years old patients, due to multiple organs decline, and then through such extreme non-physiological intervention, prone to multiple organ complications, and even lead to death "
  J-Valve technology will completely change the traditional surgical approach, easier to operate and master, can simplify the heart valve replacement process, reduce the requirements of the doctor, completely rely on the implantation of the system's own positioning device to complete the valve replacement surgery.
  Chinese Academy of Medical Sciences Fu Wai Cardiovascular Hospital Surgery Systems Management Committee Director Wang Wei said that the current European and American countries are also developing minimally invasive heart valve implantation system, but there is no comprehensive positioning device, Zhang developed by the J-Valve system Is the only heart valve system with intelligent three-dimensional positioning.
  Zhang extremely similar to the explanation, the general heart valve surgery, for the surgeon doctor's request is extremely high. But J-Valve's technical system, even the ordinary heart surgeon, can also be easy to operate. "This is like a professional camera, skilled person is very few; but now with a fool camera, ordinary people can easily shoot a good photo.
  According to reports, there are two manifestations of heart valve disease, one is mainly stenosis, one is the main closure. Previous heart valve minimally invasive technology products can only be used for narrow patients, need to use "calcification point" as a hard support, and J-Valve valve is not needed.
  "If the patient's heart valve stenosis and incomplete closure of the half, then the previous product can only be treated 50%, can not cover another 50% .J-Valve can cover the expansion, covering the other 50%, all patients can Cover. "Wang Wei told reporters.
  "This is a breakthrough in the clinical process of the day." Guo Yingjiang recalled that March 26, 2014, the first day of the clinical success of the treatment of two patients, the first patient is a valve insufficiency patients, the second case The patient is a patient with a valve stenosis.
  So far Sichuan University West China Hospital has completed a total of more than 60 patients with clinical surgery, "no cases of death, up to 97% of patients successfully cured." Guo Yingqiang said, "At present, other heart valve minimally invasive technique is not suitable for closure, Although some foreign products have tried, but the overall is not very successful.
  Compared with other heart valve minimally invasive techniques, J-Valve heart valve technology has a very special point, that is, it can treat the insufficiency. The traditional treatment can only be used to treat stenosis, J-Valve heart valve technology because of its unique design, the separation of the positioning key design makes it a very good feature and function - able to treat the discomfort.


  Look forward to an early listing
  Relevant experimental report shows that as of the end of July 2015, J-Valve technology successfully completed the established number of clinical trials, proved that J-Valve is far superior to the existing intervention valve at home and abroad, while taking the traditional interventional valve technology can not be treated Simple aortic valve regurgitation disease of the world problem; breaking the heart valve minimally invasive replacement surgery completely dominated by foreign products.
  At present, J-Valve technology has been initially in the field of valvular surgery in China to form a new treatment norms, according to clinical practice, the use of J-Valve technology for aortic valve replacement takes only 7 to 10 minutes. It is worth mentioning that clinical trials are high-risk elderly patients, the average age of 74 years of age, the highest age of 87 years of age.
  "I received an email from the former chairman of the International Society for Minimally Invasive Cardiothoracic Surgery, and he said, congratulating us on the new breakthrough in this area." Wei told reporters that after the article was published, the world's top experts in cardiac surgery Have to call, e-mail to the Chinese research team to congratulate.
  "Most of the minimally invasive valve technology used in foreign countries. J-Valve clinical trials success, marking the Chinese in this area has been catching up, and keep pace with the international." Shanghai Fudan University Zhongshan Hospital, director of Cardiovascular Surgery Wang Chunsheng evaluation, "before And now we have completely independent intellectual property rights, and has been fully recognized by international counterparts.
  According to reports, the US FDA has specifically allowed J-Valve valves can be directly in the United States into the key clinical trials, without first through the preliminary feasibility of clinical trials. Similarly, Health Canada approved the J-Valve valve replacement system as a humanitarian medical device for the treatment of patients with aortic valve.
  "We are in the Zhongshan Hospital for clinical trials of more than 40 patients, have a close follow-up, the first case is in May 2014, the latest case has been six months," Wei said, "We had to worry about New valves in the use of a period of time, there will be problems such as displacement, the patient needs second intervention, has not appeared.
  "In the case of strict procedures, the state should be appropriate to speed up the approval of the progress, and now the clinical trial has ended, many patients hope that the technology can be promoted one day earlier," an unnamed domestic top three hospital president called, "I now Can only tell the patient, and then wait patiently, this product will immediately be formally approved.
  "We expect the future of the heart valve surgery for the simple outpatient surgery in the county hospitals can do," the company vice president Wei Wei has become a medical expert, "We expect the current production capacity is 10,000 a year, Products officially listed, the first product to the Chinese market, and further to the international market for the benefit of the world 's majority of patients with heart valve.
  "At the end of June, the State Food and Drug Administration commissioned the acceptance of Jiangsu," Wujiang Economic and Technological Development Zone, deputy director of Science and Technology Gu told the "Minsheng Weekly" reporter, "our development zone for the company to set aside a land for future Expand the scale of business needs.

Contact us

这是描述信息

+86-512-63179788(WJ) | +86-512-63036288(SZ)

这是描述信息

Building4-1,Hi-Tech Park, Wujiang, Jiangsu Province, China

C21 Building, 218 Xinghu Street, Suzhou Industrial Park, China

这是描述信息

215200

FOLLOW US

这是描述信息

Mobile Website

这是描述信息

WeChat

Copyright ©  Suzhou Jiecheng Medical Technology Co., Ltd. 

这是描述信息